- Forums
- ASX - By Stock
- MSB
- Ann: 83% Survival in COVID-19 ARDS Patients with Remestemcel-L
Ann: 83% Survival in COVID-19 ARDS Patients with Remestemcel-L, page-9
-
- There are more pages in this discussion • 308 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
(20min delay)
|
|||||
Last
$1.37 |
Change
0.015(1.11%) |
Mkt cap ! $1.552B |
Open | High | Low | Value | Volume |
$1.35 | $1.37 | $1.33 | $852.5K | 631K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
10 | 28035 | $1.36 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.37 | 122345 | 5 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
6 | 5298 | 1.360 |
12 | 48981 | 1.355 |
7 | 37377 | 1.350 |
9 | 62057 | 1.345 |
11 | 150727 | 1.340 |
Price($) | Vol. | No. |
---|---|---|
1.365 | 63597 | 7 |
1.370 | 126545 | 5 |
1.375 | 36573 | 6 |
1.380 | 49373 | 5 |
1.385 | 10000 | 1 |
Last trade - 11.22am 08/11/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |
The Watchlist
EQN
EQUINOX RESOURCES LIMITED.
Zac Komur, MD & CEO
Zac Komur
MD & CEO
SPONSORED BY The Market Online